Published in Crit Rev Oncol Hematol on June 01, 2001
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
HSV Recombinant Vectors for Gene Therapy. Open Virol J (2010) 0.99
Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol (2005) 0.88
Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals. Bioimpacts (2013) 0.87
Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther (2008) 0.85
Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor. J Virol (2005) 0.83
Magnetically targeted viral envelopes: a PET investigation of initial biodistribution. IEEE Trans Nanobioscience (2008) 0.81
General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Curr Gene Ther (2013) 0.78
An overview on the development of newcastle disease virus as an anti-cancer therapy. Malays J Med Sci (2003) 0.78
Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma. J Virol (2009) 0.77
RNA interference in head and neck oncology. Oncol Lett (2016) 0.75
Specific activation of 2'-5'oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: a potential for developing hepatitis C virus targeting gene therapy. World J Gastroenterol (2009) 0.75
Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol (1992) 2.50
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet (1986) 2.04
A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol (1998) 1.89
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol (2000) 1.72
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant (2007) 1.56
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
The epidemiology of dog walking: an unmet need for human and canine health. Med J Aust (2002) 1.53
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther (2010) 1.44
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther (2006) 1.43
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther (2008) 1.41
The 19S complex of the proteasome regulates nucleotide excision repair in yeast. Genes Dev (2001) 1.36
Polyploidy, phylogeography and Pleistocene refugia of the rockfern Asplenium ceterach: evidence from chloroplast DNA. Mol Ecol (2002) 1.36
Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol (2001) 1.31
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther (2009) 1.30
Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol (1996) 1.30
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res (2000) 1.24
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24
Discovery of antibodies. BMJ (1992) 1.24
Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer (2005) 1.21
Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol (2001) 1.20
Curative one-shot systemic virotherapy in murine myeloma. Leukemia (2012) 1.20
Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther (2005) 1.19
Targeting retrovirus entry. Gene Ther (1996) 1.19
Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2011) 1.19
Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol (2003) 1.19
Apoptosis or necrosis for tumor immunotherapy: what's in a name? J Mol Med (Berl) (1999) 1.19
Targeted vectors for gene therapy. FASEB J (1995) 1.18
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 1.18
Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones? FEBS Lett (2000) 1.15
Targeting of retroviral vectors through protease-substrate interactions. Gene Ther (1996) 1.15
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther (2012) 1.12
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther (2001) 1.07
Goats' milk quackery. J Paediatr Child Health (2005) 1.07
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther (2006) 1.07
Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J (1997) 1.07
Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther (2002) 1.05
Recent clinical experience with oncolytic viruses. Curr Pharm Biotechnol (2012) 1.04
Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther (2001) 1.04
Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy? Clin Oncol (R Coll Radiol) (2005) 1.03
Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther (1996) 1.03
Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol (1998) 1.03
Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther (2006) 1.02
Genetic discontinuity, breeding-system change and population history of Arabis alpina in the Italian Peninsula and adjacent Alps. Mol Ecol (2008) 1.02
Cancer gene therapy: hard lessons and new courses. Gene Ther (2000) 1.01
A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther (2000) 0.99
Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother (2001) 0.99
Measles virus as an oncolytic vector platform. Curr Gene Ther (2008) 0.98
The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J Mol Biol (1993) 0.98
In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol (1998) 0.97
Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther (1999) 0.97
Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther (2011) 0.95
Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther (2009) 0.93
Amiodarone induced skin necrosis. Heart (2006) 0.93
Genetic diversity and phylogeography in two diploid ferns, Asplenium fontanum subsp. fontanum and A. petrarchae subsp. bivalens, in the western Mediterranean. Mol Ecol (2009) 0.92
Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther (1999) 0.91
Recombination diversifies chloroplast trnF pseudogenes in Arabidopsis lyrata. J Evol Biol (2007) 0.91
Retroviruses as vectors. Br Med Bull (1995) 0.91
Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood (1998) 0.90
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther (2013) 0.90
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer (2013) 0.90
Histological findings of birdshot chorioretinopathy in an eye with ciliochoroidal melanoma. Eye (Lond) (2012) 0.89
Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. Cancer Gene Ther (2000) 0.89
Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther (2012) 0.88
Are GPs using clinical practice guidelines? Aust Fam Physician (2001) 0.88
Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther (1999) 0.86
Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther (2003) 0.86
Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Hum Gene Ther (1999) 0.86
Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology (1995) 0.86
HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther (2013) 0.86
Viral vector targeting. Curr Opin Biotechnol (1999) 0.85
Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther (1999) 0.85
Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke. Brain Res Bull (1999) 0.85
A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther (1997) 0.85
Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther (2003) 0.85
VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther (2006) 0.85
Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther (2004) 0.84
The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles. Gene Ther (2006) 0.84
Gene transfer technologies for the gene therapy of cancer. Gene Ther (1994) 0.84
Modification of retroviral tropism by display of IGF-I. J Mol Biol (1999) 0.84
A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther (2000) 0.83
Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther (2008) 0.83
Concentration of viral vectors by co-precipitation with calcium phosphate. J Gene Med (2001) 0.83
Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther (2005) 0.82
GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther (2011) 0.82
Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther (2011) 0.82
Population structure and historical biogeography of European Arabidopsis lyrata. Heredity (Edinb) (2010) 0.82
Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Cancer Res (2000) 0.81
Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients. J Hosp Infect (1987) 0.81
Dexamethasone and the risk for adrenal suppression in multiple myeloma. Leukemia (2009) 0.81